Lexicon Pharmaceuticals (LXRX) Q2 2024 earnings summary

Executive summary

• INPEFA net sales reached $1.6 million in Q2 2024, reflecting ongoing commercialization and modest growth in heart failure despite a competitive landscape.

• ZYNQUISTA NDA was resubmitted, with a PDUFA goal date of December 20, 2024, targeting a commercial launch in early 2025 for type 1 diabetes and CKD.

• Phase III SONATA trial for sotagliflozin in HCM is underway, with broad patient inclusion and expected final data by late 2026 or early 2027.

• LX9211 phase IIB study in diabetic peripheral neuropathic pain is on track for top-line data in Q2 2025.

• LX9851, an oral obesity therapy, is advancing through preclinical and IND-enabling studies, with promising preclinical efficacy and safety.

Financial highlights

• Q2 2024 revenue was $1.6 million, up from $0.3 million in Q2 2023, driven by INPEFA sales.

• R&D expenses rose to $17.6 million from $14.5 million year-over-year, reflecting increased development activity and higher clinical research costs.

• SG&A expenses increased to $39.2 million from $30 million year-over-year, mainly due to INPEFA's commercial launch.

• Net loss for Q2 2024 was $53.4 million ($0.17/share), compared to $44.9 million ($0.22/share) in Q2 2023.

• Cash and investments at quarter-end totaled $310 million, up from $170 million at year-end 2023, following March equity financing.

Outlook and guidance

• Anticipates ZYNQUISTA launch in early 2025, pending FDA approval.

• SONATA-HCM trial aims for final data by late 2026 or early 2027, with potential for a broad label.

• LX9211 top-line phase IIB data expected in Q2 2025.

• LX9851 progressing toward clinical development, with plans for data presentations at medical meetings.

• Current cash and investments are expected to fund operations for at least the next 12 months.